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1. INTRODUCTION {#cam41728-sec-0005}
===============

Cancer patients contribute to a high proportion of emergency department (ED) utilization.[1](#cam41728-bib-0001){ref-type="ref"}, [2](#cam41728-bib-0002){ref-type="ref"} A recent study of ED utilization by cancer patients showed that the commonest ED diagnoses were similar to those of the general population (pneumonia, chest pain, and urinary tract infection).[2](#cam41728-bib-0002){ref-type="ref"} Nevertheless, many cancer patients attend ED for issues unique to their diagnoses, stage, or treatment. Hence, several studies have focused on certain subgroups, such as end‐of‐life patients,[3](#cam41728-bib-0003){ref-type="ref"}, [4](#cam41728-bib-0004){ref-type="ref"}, [5](#cam41728-bib-0005){ref-type="ref"}, [6](#cam41728-bib-0006){ref-type="ref"}, [7](#cam41728-bib-0007){ref-type="ref"}, [8](#cam41728-bib-0008){ref-type="ref"} and patients suffering from complications or side effects of chemotherapy, surgery, or radiotherapy.[9](#cam41728-bib-0009){ref-type="ref"}, [10](#cam41728-bib-0010){ref-type="ref"}, [11](#cam41728-bib-0011){ref-type="ref"}, [12](#cam41728-bib-0012){ref-type="ref"}, [13](#cam41728-bib-0013){ref-type="ref"}

A smaller cohort of cancer patients return to the ED multiple times, and become ED frequent attenders (FA), commonly defined as patients making four or more visits within a 12‐month period.[14](#cam41728-bib-0014){ref-type="ref"}, [15](#cam41728-bib-0015){ref-type="ref"}, [16](#cam41728-bib-0016){ref-type="ref"}, [17](#cam41728-bib-0017){ref-type="ref"}, [18](#cam41728-bib-0018){ref-type="ref"} Studies that examine general ED patients have shown that FAs have a higher chronic disease burden, different socioeconomic profiles,[14](#cam41728-bib-0014){ref-type="ref"}, [17](#cam41728-bib-0017){ref-type="ref"}, [18](#cam41728-bib-0018){ref-type="ref"}, [19](#cam41728-bib-0019){ref-type="ref"}, [20](#cam41728-bib-0020){ref-type="ref"} and higher utilization of nonemergent healthcare services.[15](#cam41728-bib-0015){ref-type="ref"}, [16](#cam41728-bib-0016){ref-type="ref"} Yet, little is known about cancer patients who become FAs.

We hypothesized that some cancer patients were at higher risk of becoming FAs due to disease‐specific symptomology and oncologic management. Defining cancer‐specific risk factors for FA would be critical in the identification of patients with unmet needs. This could present opportunities for improving the quality of cancer care, both in the ED itself,[21](#cam41728-bib-0021){ref-type="ref"} as well as in the community, with the ultimate goal of reducing the need for ED visits.[2](#cam41728-bib-0002){ref-type="ref"} Therefore, the primary objective of this study was to identify risk factors for FA by cancer patients using a national database of all patients treated in public sector hospitals. The secondary objective was to examine the trajectory of FA patients after they became FA, including their subsequent survival, and time to repeat FA. Survival from FA would clarify whether the ED visits were mostly at the end‐of‐life phase of the disease, while repeat FA would suggest that these patients continued to have high ED utilization and unmet needs.

2. METHODS {#cam41728-sec-0006}
==========

2.1. Study design, setting, data sources, and participants {#cam41728-sec-0007}
----------------------------------------------------------

This national retrospective cohort study was conducted using administrative data of ED visits, inpatient admissions, and financial claims from the Ministry of Health.[22](#cam41728-bib-0022){ref-type="ref"} Inclusion criteria were as follows: Singapore residents, alive at discharge, primary discharge diagnosis of cancer by International Classification of Diseases codes (ICD‐10‐AM: C00 ‐ C96), from January 2012 to December 2015. Death data as of 31 December 2015 were obtained from the Singapore Registry of Births and Deaths.

2.2. Variables {#cam41728-sec-0008}
--------------

Demographic information (age, gender, ethnicity) was obtained from claims data.

Socioeconomic variables were derived from mapping residential postal codes to housing type,[23](#cam41728-bib-0023){ref-type="ref"} eligibility for subsidized primary care under the Community Health Assist Scheme (CHAS),[22](#cam41728-bib-0022){ref-type="ref"} and receiving financial assistance from the government Medifund[22](#cam41728-bib-0022){ref-type="ref"} scheme for the index hospitalization.

The first hospitalization during the study period with a primary diagnosis of cancer was considered the index hospitalization. Clinical information was extracted from discharge diagnoses (cancer sites, comorbidities) and admission record (length of stay, discharge destination) for the index hospitalization. Patients were designated as FA once they made four or more ED visits within any 12‐month period during the study period after discharge from the index hospitalization. The outcome variable, time to FA, was the time from discharge from index hospitalization to meeting FA criteria. Patients who died without meeting FA criteria were censored at their date of death, while those who were still alive at the end of the study period were censored as at 31 December 2015. Patients who died after fulfilling FA criteria were still considered FA and not censored.

Primary cancer sites were grouped by two‐digit ICD‐10‐AM codes according to the US National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) codes for cancers deemed to be single‐site primaries.[24](#cam41728-bib-0024){ref-type="ref"} Metastases were grouped by three‐digit codes into brain, bone, lymph node, lung, liver, other gastrointestinal, and other metastases. Primary cancer sites with low event rates (fewer than ten patients becoming FA) were regrouped (Table [S1](#cam41728-sup-0001){ref-type="supplementary-material"}).

2.3. Statistical analysis {#cam41728-sec-0009}
-------------------------

Time to FA distribution was estimated using Kaplan‐Meier method, and factors associated with risk of FA were identified using multivariable Cox regression analyses. The following variables were examined in the main Cox model: age at index admission, gender, Charlson comorbidity index (excluding cancer variables, unadjusted for age), primary and metastatic sites of cancer, length of stay, discharge destination, and socioeconomic variables.

Additional sensitivity analyses of the main Cox model were performed: (a) Cancer sites classified based on original ICD‐10‐AM two‐digit codes (without regrouping according to SEER codes, in the event that sites that may be biologically similar but cause different symptoms); (b) cancer sites classified by SEER groups, with low event rate primary sites all grouped into a single category "others" (to examine the cancer primary sites without any attempt at forced grouping of similar "rare" primary sites); (c) excluding patients with missing ethnicity and/or housing type; (d) including interaction terms for ethnicity and all three socioeconomic indicators (Medifund use, income percentile, and housing type); (e) excluding patients aged \<17 years (to examine the adult population without the effect of pediatric‐dominant tumors); and (f) addition of interaction terms for age‐group and the cancer types known to be more common in pediatric and young adult age‐groups.

For the secondary analysis of the trajectory of FA patients, survival was measured, from the day the patient first met FA criteria to the day of death. To examine patients with continued high unmet needs after becoming FA, ED visits were examined for the subsequent 12‐month period after the patient first met FA criteria. Time to repeat FA was measured, from the day the patient first met FA criteria to the day the patient made an additional four or more ED visits.

STATA (version 13.0, StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP.) was used to perform statistical analyses, and a two‐sided *P*‐value \< 0.05 was considered statistically significant.

2.4. Missing data {#cam41728-sec-0010}
-----------------

The only variables with missing data in this study were housing type (7149, 15.1%) and ethnicity (5971, 12.6%). Impact of missing data on the identification of risk factors for FA was evaluated via sensitivity analysis set (3). No imputation was performed.

2.5. Potential bias {#cam41728-sec-0011}
-------------------

As this study was limited to public hospitals in Singapore, we could not capture the private hospital admissions and ED visits. Hence, some of the non‐FAs in this study, especially patients with better insurance coverage, may have in fact been FAs, if private hospital ED visits had been captured. However, the majority of health care by Singapore residents is provided by public hospitals[22](#cam41728-bib-0022){ref-type="ref"}; hence, we expect this effect to be minimal.

2.6. Ethical approval {#cam41728-sec-0012}
---------------------

The first author\'s (Singapore General Hospital) Institutional Review Board granted ethical approval for this study.

3. RESULTS {#cam41728-sec-0013}
==========

Of the 47 235 cancer patients identified, 2980 became FAs during the study period (Figure [1](#cam41728-fig-0001){ref-type="fig"}). The cumulative incidence rate of FA was 7.0% by 1 year postdischarge, 9.0% at 2 years, and 10.3% at 3 years (Figure [2](#cam41728-fig-0002){ref-type="fig"}). FA accounted for 35.4% of all ED visits made after discharge from hospitalization (Tables [1](#cam41728-tbl-0001){ref-type="table"} and [2](#cam41728-tbl-0002){ref-type="table"}). A higher proportion of FA patients who died during the study period died in the acute hospital (53.8%) compared to non‐FA patients (44.5%; *P* \< 0.001).

![Flowchart for selection of study population](CAM4-7-4434-g001){#cam41728-fig-0001}

![Cumulative incidence of FA, entire study population](CAM4-7-4434-g002){#cam41728-fig-0002}

###### 

Patient characteristics---demographics, admission characteristics, comorbidities

                                                                Total        Nonfrequent attenders   Frequent attenders                    
  ------------------------------------------------------------- ------------ ----------------------- -------------------- ------- -------- -------
  Total                                                         47 235       100.0                   44 255               100.0   2980     100.0
  Demographics                                                                                                                             
  Gender                                                                                                                                   
  Male                                                          22 703       48.1                    20 924               47.3    1779     59.7
  Female                                                        24 532       51.9                    23 331               52.7    1201     40.3
  Age, years                                                                                                                               
  Age \< 17                                                     821          1.7                     709                  1.6     112      3.8
  17‐34                                                         1825         3.9                     1758                 4.0     67       2.2
  35‐44                                                         3156         6.7                     3048                 6.9     108      3.6
  45‐54                                                         7315         15.5                    6973                 15.8    342      11.5
  55‐64                                                         12 332       26.1                    11 586               26.2    746      25.0
  65‐74                                                         11 557       24.5                    10 787               24.4    770      25.8
  75‐84                                                         7853         16.6                    7211                 16.3    642      21.5
  85 and above                                                  2376         5.0                     2183                 4.9     193      6.5
  Median (IQR)                                                  63 (53‐73)   62 (52‐72)              65 (56‐75)                            
  Ethnicity                                                                                                                                
  Chinese                                                       33 320       70.5                    31 095               70.3    2225     74.7
  Indian                                                        2029         4.3                     1822                 4.1     207      7.0
  Malay                                                         3893         8.2                     3523                 8.0     370      12.4
  Other                                                         2022         4.3                     1882                 4.3     140      4.7
  Missing                                                       5971         12.6                    5933                 13.4    38       1.3
  Socioeconomic                                                                                                                            
  Medifund use                                                                                                                             
  Yes                                                           3218         6.813                   2909                 6.6     309      10.4
  Income percentile                                                                                                                        
  \>50th percentile                                             32 293       68.4                    30 413               68.7    1880     63.1
  20th‐50th percentile                                          2868         6.1                     2690                 6.1     178      6.0
  \<20th percentile                                             12 074       25.6                    11 152               25.2    922      30.9
  Housing subsidy                                                                                                                          
  One‐ or two‐room housing development board (HDB) apartments   1861         3.9                     1645                 3.7     216      7.3
  Three‐room HDB                                                10 334       21.9                    9526                 21.5    808      27.1
  Four‐room HDB                                                 12 931       27.4                    11 972               27.1    959      32.2
  Five‐room or Executive HDB                                    9342         19.8                    8758                 19.8    584      19.6
  Private housing (condominium/landed)                          5618         11.9                    5316                 12.0    302      10.1
  Missing                                                       7149         15.1                    7038                 15.9    111      3.7
  Charlson comorbidity index (CCI)                                                                                                         
  CCI = 0                                                       29 001       61.4                    27 803               62.8    1198     40.2
  CCI = 1                                                       8125         17.2                    7527                 17.0    598      20.1
  CCI = 2                                                       3475         7.4                     3135                 7\.     340      11.4
  CCI = 3                                                       2326         4.9                     2096                 4.7     230      7.7
  CCI ≥ 4                                                       4308         9.1                     3694                 8.4     614      20.6
  Median (IQR)                                                  0 (0‐1)      0 (0‐1)                 1 (0‐3)                               
  Index admission                                                                                                                          
  Length of stay (IQR)/d                                        5 (2‐9)      6 (2‐11)                5 (2‐9)                               
  Discharged                                                    42 328       89.6                    39 664               89.6    2664     89.4
  Transferred                                                   2617         5.5                     2447                 5.5     170      5.7
  Others                                                        2290         4.9                     2144                 4.8     146      4.9
  ED visits (after index admission)                                                                                                        
  Total visits made                                             56 532       100.0                   36 516               100.0   20 016   100.0
  Weekend visit                                                 8213         14.5                    5394                 14.8    2819     14.1
  Weekday visit                                                 48 319       85.5                    31 122               85.2    17 197   85.9
  Median ED visits per patient (IQR)                            0(0‐2)       0(0‐1)                  6(4‐8)                                
  Death                                                                                                                                    
  Deaths during study period                                    15 306                               13 411                       1895     
  Death in acute hospital                                       6985         45.6                    5966                 44.5    1019     53.8
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###### 

Patient characteristics---cancer sites

  Primary and secondary sites                                          Total    Nonfrequent attenders   Frequent attenders                  
  -------------------------------------------------------------------- -------- ----------------------- -------------------- ------- ------ -------
  Total                                                                47 235   100.0                   44 255               100.0   2980   100.0
  Primary sites                                                                                                                             
  Other head and neck C00, C03, C04, C05, C06, C14                     213      0.5                     197                  0.5     16     0.5
  Tongue C01, C02                                                      346      0.7                     318                  0.7     28     0.9
  Oropharynx C9, C10                                                   97       0.2                     84                   0.2     13     0.4
  Nasopharynx C11                                                      591      1.3                     526                  1.2     65     2.2
  Hypopharynx C12, C13                                                 103      0.2                     87                   0.2     16     0.5
  Esophagus C15                                                        441      0.9                     378                  0.9     63     2.1
  Stomach C16                                                          1894     4.0                     1724                 3.9     170    5.7
  Small intestine C17                                                  168      0.4                     157                  0.4     11     0.4
  Colon C18                                                            4767     10.1                    4464                 10.1    303    10.2
  Rectosigmoid C19                                                     1071     2.3                     993                  2.2     78     2.6
  Rectum C20                                                           1666     3.5                     1540                 3.5     126    4.2
  Anus C21                                                             119      0.3                     107                  0.2     12     0.4
  Liver C22                                                            3264     6.9                     3012                 6.8     252    8.5
  Biliary C23, C24                                                     510      1.1                     469                  1.1     41     1.4
  Pancreas C25                                                         1306     2.8                     1201                 2.7     105    3.5
  Other facial C30, C31, C69                                           204      0.4                     192                  0.4     12     0.4
  Larynx C32                                                           356      0.8                     326                  0.7     30     1.0
  Trachea and lung C33, C34                                            5447     11.5                    5041                 11.4    406    13.6
  Thymus, heart, mediastinum C37, C38                                  195      0.4                     187                  0.4     8      0.3
  Bone C40, C41                                                        224      0.5                     208                  0.5     16     0.5
  Skin C43, C44, C46                                                   703      1.5                     668                  1.5     35     1.2
  Mesothelioma, pleural C45, C384                                      126      0.3                     107                  0.2     19     0.6
  Other soft tissue sarcoma C47, C49                                   398      0.8                     375                  0.9     23     0.8
  Retroperitoneum C48                                                  202      0.4                     191                  0.4     11     0.4
  Breast C50                                                           7013     14.9                    6761                 15.3    252    8.5
  Female genital C51, C52, C57.7, C57.8‐9                              161      0.3                     150                  0.3     11     0.4
  Cervix C53                                                           989      2.1                     957                  2.2     32     1.1
  Uterus C54, C55                                                      1670     3.5                     1632                 3.7     38     1.3
  Ovary C56, C57.0, C57.1, C57.2, C57.3, C57.4                         1379     2.9                     1331                 3.0     48     1.6
  Male genital C60, C62, C63                                           257      0.5                     245                  0.6     12     0.4
  Prostate C61                                                         1915     4.1                     1797                 4.1     118    4.0
  Kidney and ureter C64, C65, C66, C68                                 1589     3.4                     1468                 3.3     121    4.1
  Bladder C67                                                          1179     2.5                     1073                 2.4     106    3.6
  Brain, spine C70, C71, C72                                           668      1.4                     598                  1.4     70     2.4
  Thyroid C73                                                          1698     3.6                     1673                 3.8     25     0.8
  Adrenal and endocrine C74, C75                                       100      0.2                     84                   0.2     16     0.5
  Other miscellaneous malignancies C7, C8, C26, C58, C76               329      0.7                     314                  0.7     15     0.5
  Unspecified site C80                                                 718      1.5                     657                  1.5     61     2.1
  Hodgkin\'s disease C81                                               169      0.4                     163                  0.4     6      0.2
  Follicular non‐Hodgkin\'s lymphoma (nodular) C82                     201      0.4                     188                  0.4     13     0.4
  Diffuse non‐Hodgkin\'s lymphoma C83                                  1106     2.3                     1024                 2.3     82     2.8
  Peripheral and cutaneous T‐cell lymphomas C84                        183      0.4                     171                  0.4     12     0.408
  Other and unspecified types of non‐Hodgkin\'s lymphoma C85           446      0.9                     420                  1.0     26     0.9
  Miscellaneous immunoproliferative diseases C88, C93, C94, C95, C96   142      0.3                     128                  0.3     14     0.5
  Multiple myeloma and malignant plasma cell neoplasms C90             471      1.0                     437                  1.0     34     1.1
  Lymphoid leukemia C91                                                559      1.2                     503                  1.1     56     1.9
  Myeloid leukemia C92                                                 756      1.6                     723                  1.6     33     1.1
  More than one primary site                                           1378     2.9                     1267                 2.9     111    3.7
  Secondary sites                                                                                                                           
  Lymph node metastases C77                                            9013     19.1                    8485                 19.2    528    17.7
  Lung metastases C780, C781, C782, C783                               4966     10.5                    4627                 10.5    339    11.4
  Gastrointestinal metastases C784, C785, C786, C788                   2553     5.4                     2408                 5.4     145    4.9
  Liver metastases C787                                                4005     8.5                     3747                 8.5     258    8.7
  Bone metastases C795                                                 3843     8.1                     3564                 8.1     279    9.4
  Brain metastases C793                                                1618     3.4                     1494                 3.4     124    4.2
  Other metastases C792, C794, C796, C797, C798, C790, C791            1991     4.2                     1868                 4.2     123    4.1
  More than one secondary site                                         6172     13.1                    5753                 13.0    419    14.1
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3.1. Risk factors for FA {#cam41728-sec-0014}
------------------------

These factors were associated with an increased risk of FA: age (\<17 years, hazard ratio \[HR\] 2.92, 95% CI 2.28‐3.74; 75‐84 years, HR 1.29, 95% CI 1.16‐1.45; and \>85 years, HR 1.71, 95% CI 1.45‐2.02, relative to age 55‐64), male gender (HR 1.26, 95% CI 1.16‐1.37), Charlson comorbidity index (HR 1.21, 95% CI 1.19‐1.23), and socioeconomic factors (Medifund use, HR 1.40, 95% CI 1.23‐1.59; housing subsidy type, HR 2.12, 95% CI 1.77‐2.54).

The following primary sites were risk factors for FA: brain and spine (HR 2.51, 95% CI 1.67‐3.75), head and neck cancers (tongue, HR 2.05, 95% CI 1.27‐3.31; oropharynx, HR 2.32, 95% CI 1.29‐4.21; hypopharynx, HR 2.72, 95% CI 1.56‐4.74), lung (trachea and lung, HR 1.57, 95% CI 1.13‐2.18; pleural, HR 3.69, 95% CI 2.12‐6.34), upper gastrointestinal (stomach, HR 1.93, 95% CI 1.26‐2.74; esophagus, HR 4.13, 95% CI 2.78‐6.13), hepato‐pancreato‐biliary (liver, HR 1.42, 95% CI 1.01‐2.00; biliary, HR 2.16, 95% CI 1.40‐3.35; pancreas, HR 2.48, 95% CI 1.72‐3.59), certain hematological malignancies (diffuse non‐Hodgkin\'s lymphoma, HR 1.59, 95% CI 1.08‐2.33; lymphoid leukemia, HR 1.86, 95% CI 1.21‐2.86; miscellaneous hematological malignancies, HR 2.14, 95% CI 1.16‐3.96), and unknown primary (HR 1.98, 95% CI 1.33‐2.95). Patients with thyroid (HR 0.35, 95% CI 0.21‐0.57) and uterine (HR 0.52, 95% CI 0.33‐0.81) primary sites were less likely to become FA. Among the secondary sites, metastases to brain (HR 1.69, 95% CI 1.27‐2.26), lung (HR 1.31, 95% CI 1.01‐1.71), liver (HR 1.46, 95% CI 1.14‐1.89), and bone (HR 1.35, 95% CI 1.04‐1.76) increased the risk of becoming FA (Figure [3](#cam41728-fig-0003){ref-type="fig"}).

![Risk factors for ED frequent attender](CAM4-7-4434-g003){#cam41728-fig-0003}

When the high‐risk known primary sites were further grouped into six related groups (brain and spine; esophageal and gastric; liver, pancreatic, and biliary; lung, trachea, pleural, and mesothelioma; head and neck; and diffuse non‐Hodgkin\'s lymphoma and lymphoid leukemia), increase in the cumulative incidence of FA rates among patients with solid tumors occurred steadily over the first 3 years postdischarge from index hospitalization, whereas those of patients with hematological malignancies occurred mainly in the first year (Figure [4](#cam41728-fig-0004){ref-type="fig"}).

![Cumulative incidence of FA, by groups of high‐risk primary sites: (a) Brain and spine (brain and spine). (b) Diffuse non‐Hodgkin\'s lymphoma and lymphoid leukemia (DNHL and LL). (c) Nasopharynx, base of tongue, other parts of tongue, tonsil, oropharynx, nasopharynx, piriform sinus, hypopharynx (head and neck). d. Liver, pancreatic, and biliary (hepatobiliary). (e) Lung, trachea, pleural and mesothelioma (lung and TPM). (f) Esophageal and gastric (upper GI)](CAM4-7-4434-g004){#cam41728-fig-0004}

In the sensitivity analysis model incorporating socioeconomic factors and ethnicity, interaction effects were seen between ethnicity and housing type and between income percentile and housing type. While socioeconomic variables remained significant risk factors for FA, there was no longer a significant association between ethnicity and risk of FA. This suggested that the ethnic differences in time to FA were reflecting differences in socioeconomic status of patients.

In the model in which patients aged \<17 years were excluded, patients with gastrointestinal metastases more likely to become FA. In the model including interaction terms between age‐groups and the cancer types known to be more common in pediatric and young adults, the interaction term between age less than 17 and the brain and spine primary tumors was significant. In the model using individual ICD‐10‐AM cancer sites (without the SEER regrouping), breast (C50) and ovarian cancer (C56) patients were less likely to become FA. All other risk factors remained unchanged in the sensitivity analyses.

3.2. Trajectory after becoming FA {#cam41728-sec-0015}
---------------------------------

Of the 2980 FA, 39.2% died within 3 months of becoming FA. The 6‐month and 12‐month cumulative mortality rates of FA were 51.5% and 62.5%, respectively. Of the six high‐risk primary site groups, diffuse non‐Hodgkin\'s lymphoma and lymphoid leukemia patients had the highest 12‐month survival rate of 69.9%, followed by brain and spine patients at 46.4%. The remaining solid tumor patients had a 12‐month survival rate of 17.6%‐31.9% (Figure [5](#cam41728-fig-0005){ref-type="fig"}A).

![A, Cumulative mortality after FA (%), by groups of high‐risk primary sites: (a) Brain and spine (brain and spine). (b) Diffuse non‐Hodgkin\'s lymphoma and lymphoid leukemia (DNHL and LL). (c) Nasopharynx, base of tongue, other parts of tongue, tonsil, oropharynx, nasopharynx, piriform sinus, hypopharynx (head and neck). (d) Liver, pancreatic, and biliary (hepatobiliary). (e) Lung, trachea, pleural, and mesothelioma (Lung and TPM). (f) Esophageal and gastric (upper GI). B, Cumulative incidence of second FA (%), by groups of high‐risk primary sites: (a) Brain and spine (brain and spine). (b) Diffuse non‐Hodgkin\'s lymphoma and lymphoid leukemia (DNHL and LL). (c) Nasopharynx, base of tongue, other parts of tongue, tonsil, oropharynx, nasopharynx, piriform sinus, hypopharynx (head and neck). (d) Liver, pancreatic, and biliary (hepatobiliary). (e) Lung, trachea, pleural, and mesothelioma (Lung and TPM). (f) Esophageal and gastric (upper GI)](CAM4-7-4434-g005){#cam41728-fig-0005}

Over 40% of FA patients made another four or more ED visits within the 12‐month period after becoming FA. The hepatobiliary group had the highest 12‐month cumulative incidence rates of repeat FA (Figure [5](#cam41728-fig-0005){ref-type="fig"}B).

4. DISCUSSION {#cam41728-sec-0016}
=============

Despite being heavy users of ED services, specific factors that put cancer patients at risk of becoming FA have yet to be defined. In this study, we found that age, male gender, comorbidities, socioeconomic factors, and certain cancer sites were associated with higher risk of FA. Patients admitted with cancer sites associated with better prognoses (breast, thyroid, uterine, or ovarian primaries) were less likely to become FA. This result is consistent with other ED studies showing proportionately fewer breast cancer patients.[1](#cam41728-bib-0001){ref-type="ref"}, [9](#cam41728-bib-0009){ref-type="ref"} Longer length of stay of index hospitalization and the need for transfer to another acute hospital likely reflected the complexity of treatment required, although social factors could also affect length of stay.

To our knowledge, this study is the first to examine ED frequent attendance by cancer patients as a whole and to identify disease‐specific risk factors for high ED utilization. Most studies have focused on specific cancer subpopulations, such as end‐of‐life patients. A recent meta‐analysis of ED utilization in end‐of‐life cancer patients found that male gender, ethnic minority, low socioeconomic status, and lung cancer were independent risk factors for increased ED utilization.[7](#cam41728-bib-0007){ref-type="ref"} Our study revealed additional risk factors associated with FA. We included patients that had recently undergone curative oncologic treatment, rather than limiting the analyses to end‐of‐life patients. Furthermore, given the cohort size and diversity of diagnoses, we were able to divide the malignancies by specific diagnoses rather than collective groups such as "all gastrointestinal" cancers.[5](#cam41728-bib-0005){ref-type="ref"}, [25](#cam41728-bib-0025){ref-type="ref"} This could account for the positive correlation between a diagnosis of esophageal, stomach, liver, pancreatic or biliary cancer and FA, as each of these was analyzed independently of neutral‐risk gastrointestinal cancers, such as colorectal cancer patients, which account for the largest group of gastrointestinal cancers in most populations. Another study has also reported a high proportion of head and neck cancer patients utilizing ED,[5](#cam41728-bib-0005){ref-type="ref"} similar to the findings in our study, but again, this was in the end‐of‐life setting.

Many smoking‐associated cancers (lung, esophageal, head and neck) were associated with FA. The increased risk of FA for these patients could be compounded by the burden of smoking‐related noncancer comorbidities, concordant with the finding that Charlson comorbidity index was significant in our model. Lung cancer, known to be a resource‐intensive cancer primary site,[26](#cam41728-bib-0026){ref-type="ref"}, [27](#cam41728-bib-0027){ref-type="ref"} was the most common cancer in the FA group. The less common brain and spine primary sites would likely cause a rapid decline in independence, even before patients succumb to their disease. Our study found that the risk of FA was even higher for several other primary malignancies (liver, pancreatic, biliary, esophageal, stomach, brain and spine, head and neck). One commonality for several of the FA risk cancer primaries (esophageal, gastric, liver, pancreatic, biliary, lung, trachea, pleural, head and neck cancers) is the requirement for tubes, stents, or other paraphernalia that can be dislodged, blocked, or have a number of technical issues not easily managed in the community. These include biliary stents for hepatobiliary sepsis, endoscopic feeding tubes for upper gastrointestinal blockage, pleural drainage tubes for lung effusions, tracheostomy, and feeding tubes for the head and neck cancers. We plan to focus our future analyses on the contribution of these paraphernalia to ED visits due to blockage or displacement, and examine the chronologic relationship between ED attendances and cancer‐specific treatment.

In contrast, FA among lymphoma and leukemia patients is likely explained by infectious complications arising from myelotoxic and immunosuppressive treatment, with patients at continued risk throughout the course of treatment. This may explain the difference in the shape of cumulative incidence of FA curves for these patients, when compared to the patients with high‐risk solid tumors.

Secondary analyses of the trajectory of FA patients after they became FA yielded additional insights. The significant proportion of cancer patients who became FA before the end of life highlighted the additional ED burden and unmet needs for patients whose life expectancy would exceed qualifying for hospice care. Many end‐of‐life studies focus on ED visits in the last 2 weeks, 30 days or 6 months of life,[3](#cam41728-bib-0003){ref-type="ref"}, [6](#cam41728-bib-0006){ref-type="ref"}, [7](#cam41728-bib-0007){ref-type="ref"} or once advanced disease is diagnosed.[5](#cam41728-bib-0005){ref-type="ref"} While end‐of‐life care is an important trigger for ED visits and unplanned admission, studies focusing only on end‐of‐life ED utilization could include patients attending ED for terminal care, but whose overall ED utilization was not high. Our study shows the utility of applying definitions of high ED utilization (four or more visits in 12 months) to cancer patients regardless of survival, suggesting that specific cancer types are associated with FA.

Many FA patients became repeat FA in the 12 months after they first met FA criteria. A higher proportion of FA patients died in an acute hospital compared to non‐FA patients, possibly reflecting a higher degree of unmet needs. With the improved survival from advances in cancer treatment, and the resulting increased life expectancy for patients with advanced disease, patients with the risk factors identified in our study may benefit from additional support, regardless of life expectancy. We hope these results can inform healthcare planning needs for these high‐risk groups of patients. For example, for FA groups who have high mortality after becoming FA (upper gastrointestinal, hepatobiliary, head and neck, lung), it is likely that high intensity and earlier introduction of end‐of‐life care would be helpful. In contrast, for FA groups who have high repeat FA within the subsequent 12 months, and yet have reasonable survival (hematological malignancies, brain and spine), alternative support measures may be needed.

We believe that the data presented here can be translated to First World countries. Singapore is an urban country with long life expectancy and a well‐developed healthcare system. Access to a nationwide billing database allowed accurate identification and definition for the cohort examined, and hence the large sample size and the good quality of data linkage. We found a low proportion of deaths in ED, probably reflecting good access to hospice services.[28](#cam41728-bib-0028){ref-type="ref"}

Some aggressive cancers (eg, melanoma) common in Western populations were rare in our study population, and hence, the numbers in our study could be too low to manifest FA risk factors for these cancers. In addition, the low numbers of pediatric and young adult patients in the study (as expected of a small country with an aging population and low birth rate), make it difficult to further stratify at‐risk age‐groups for pediatric and young adult tumors. Hence, it would be good for researchers with access to data with higher numbers of pediatric and young adult patients to focus on these tumors in future studies. Nevertheless, our findings should be generalizable for the cancers positively associated with FA in our study.

One limitation was that we could not link our data to the various independent home hospice organizations in Singapore; hence, we could not examine the effect of timely referral and frequency of home hospice visits on ED utilization, shown to reduce ED utilization.[4](#cam41728-bib-0004){ref-type="ref"}, [29](#cam41728-bib-0029){ref-type="ref"}, [30](#cam41728-bib-0030){ref-type="ref"} The majority of dying cancer patients in Singapore receive community hospice services,[31](#cam41728-bib-0031){ref-type="ref"} and the high‐risk groups we found in our study may benefit from the early referral.

5. CONCLUSIONS {#cam41728-sec-0017}
==============

There are both clinical and socioeconomic risk factors for FA suffering from cancer, and the high‐risk groups of cancer patients identified in this study may benefit from targeted models of care. These findings provide an important framework to institute the necessary multidisciplinary support structures to prevent these attendances. Improving care coordination and expansion of existing community resources to support these patient groups should be considered when planning emergency and oncologic services, as this is clearly an urgent unmet clinical need.
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